Apollo‐2: a randomized, placebo and active‐controlled phase III study investigating oliceridine (TRV 130), a G protein–biased ligand at the μ‐opioid receptor, for …

NK Singla, F Skobieranda, DG Soergel… - Pain …, 2019 - Wiley Online Library
Objectives The clinical utility of conventional IV opioids is limited by the occurrence of opioid‐
related adverse events. Oliceridine is a novel G protein–biased μ‐opioid receptor agonist …
被引用次数：146 相关文章

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor …

NK Singla, F Skobieranda, DG Soergel, M Salamea… - Pain Practice, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Objectives</jats: title>< jats: p>
The clinical utility of conventional IV opioids is limited by the occurrence of opioid‐related …

APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for …

NK Singla, F Skobieranda… - Pain practice: the …, 2019 - pubmed.ncbi.nlm.nih.gov
Objectives The clinical utility of conventional IV opioids is limited by the occurrence of opioid-
related adverse events. Oliceridine is a novel G protein-biased μ-opioid receptor agonist …
[HTML] nih.gov

[HTML][HTML] APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid …

NK Singla, F Skobieranda, DG Soergel, M Salamea… - Pain …, 2019 - ncbi.nlm.nih.gov
Objectives The clinical utility of conventional IV opioids is limited by the occurrence of opioid‐
related adverse events. Oliceridine is a novel G protein–biased μ‐opioid receptor agonist …

APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for …

NK Singla, F Skobieranda, DG Soergel… - Pain Practice: the …, 2019 - europepmc.org
Objectives The clinical utility of conventional IV opioids is limited by the occurrence of opioid-
related adverse events. Oliceridine is a novel G protein-biased μ-opioid receptor agonist …

APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for …

NK Singla, F Skobieranda, DG Soergel… - Pain Practice: the …, 2019 - europepmc.org
Objectives The clinical utility of conventional IV opioids is limited by the occurrence of opioid-
related adverse events. Oliceridine is a novel G protein-biased μ-opioid receptor agonist …